Business Context and Reporting Period
Company: Midatech Pharma PLC (Note: Input metadata referenced "Biodexa," but the filing text identifies the registrant as Midatech Pharma PLC).
Reporting Period: Fiscal year ended December 31, 2016.
Business Overview: Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas. Its strategy involves internal development of oncology products using two proprietary drug delivery platforms (Gold Nanoparticles and Sustained Release) and commercialization of acquired products through its US subsidiary, Midatech US (formerly DARA BioSciences). Key commercial products include Zuplenz, Gelclair, Oravig, and Soltamox.
Key Financial Metrics (Year Ended Dec 31, 2016)
| Metric | 2016 (GBP '000s) | 2015 (GBP '000s) |
|---|---|---|
| Revenue | 6,376 | 775 |
| Total Revenue (incl. Grants) | 6,923 | 1,375 |
| Loss from Operations | (30,586) | (12,918) |
| Loss Before Tax | (29,322) | (11,232) |
| Net Loss (Attributable to Owners) | (20,162) | (10,099) |
| Cash and Cash Equivalents | 17,608 | 16,175 |
| Total Assets | 56,689 | 64,041 |
| Total Liabilities | 10,965 | 17,154 |
| Borrowings | 1,620 | 1,508 |
| Working Capital | 12,958 | 11,232 |
Note: Financial statements are prepared in British Pounds Sterling (GBP) in accordance with IFRS.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 718% to £6.38 million, driven by the inclusion of a full year of results from the Midatech US business (acquired Dec 2015) and growth in the product portfolio.
- Operating Loss Expansion: Operating loss widened to £30.6 million from £12.9 million. This was primarily due to:
- Impairment Charge: A one-time non-cash impairment of £11.41 million on marketing and product rights for the product Oravig due to underperformance in a heavily genericized market.
- Increased Expenses: Distribution, sales, and marketing costs rose 2,446% to £9.52 million due to the consolidation of Midatech US operations. Administrative costs increased 16% to £9.22 million.
- Net Loss: Net loss attributable to owners increased to £20.16 million, partially offset by a £9.16 million tax credit (including £4.6 million deferred tax benefit related to the impairment charge).
- Capital Structure: In October 2016, the company raised £15.6 million net proceeds via a placing and open offer. As of Feb 2017, a £6.0 million senior secured loan facility with Silicon Valley Bank was announced (undrawn at year-end).
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects to continue incurring losses for the foreseeable future as it advances clinical development and seeks regulatory approvals. The company believes its existing cash reserves (£17.6 million) and the new loan facility will fund operations for at least the next 12 months. Revenue growth is expected to be driven by Midatech US commercial operations and potential licensing deals, with in-house product commercialization targeted for 2018-2019.
Unusual Items
- Intangible Asset Impairment: £11.41 million charge related to Oravig product rights due to sales underperformance.
- Derivative Liability Gain: Finance income included a £1.17 million gain from the revaluation of equity-settled derivative financial liabilities (warrants/options assumed in the DARA acquisition).
Risks and Contingencies
- Internal Control Weaknesses: The company identified a material weakness in internal controls regarding the incorrect presentation of credits for product returns/rebates (recorded as cost of sales rather than revenue reduction) and a prior weakness regarding the accounting treatment of share options/warrants. Remediation is underway.
- Liquidity: The company has an accumulated deficit of £59.11 million and relies on future financing or product revenue to sustain operations.
- Product Performance: Significant risk associated with the commercial success of Oravig and the ability to gain market share in genericized markets.
- Regulatory & Clinical: Risks related to the success of clinical trials for pipeline candidates (e.g., Q-Octreotide) and regulatory approvals in the US and EU.
- Contingent Value Rights (CVRs): Potential future liability of up to $3.325 million to former DARA stockholders based on sales milestones for Oravig and Gelclair in 2017 (targets not met in 2016).
Key Facts for Investor Verification
- Impairment Validity: Verify the assumptions used in the £11.4 million impairment charge for Oravig and the current sales trajectory of the product.
- Cash Runway: Confirm the burn rate and whether the £17.6 million cash balance plus the undrawn £6.0 million loan facility is sufficient to fund operations through 2018 without further dilution.
- Internal Controls: Review the status of remediation for the identified material weaknesses in financial reporting to ensure future financial statements are reliable.
- Revenue Recognition: Scrutinize the correction of revenue recognition regarding sales allowances and rebates to ensure accurate future reporting.
- CVR Obligations: Monitor 2017 sales of Oravig and Gelclair to assess the likelihood of triggering the contingent value rights payments.